Angelman Syndrome Pipeline Analysis Report 2026

Report Coverage

The Angelman Syndrome Pipeline Insight Report by Expert Market Research gives comprehensive insights into Angelman syndrome therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Angelman syndrome. The Angelman syndrome report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The Angelman syndrome pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with Angelman syndrome treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to Angelman syndrome.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Angelman Syndrome Pipeline Outlook

Angelman syndrome is a rare neurogenetic disorder caused by the loss or malfunction of the UBE3A gene on chromosome 15, primarily inherited from the mother. It leads to developmental delays, lack of speech, seizures, and problems with balance and movement. The condition typically arises due to genetic mutations or deletions affecting maternal gene expression.

Angelman syndrome treatment focuses on managing symptoms through anti-seizure medications, physical therapy, speech therapy, and behavioral interventions. There is no cure, but supportive care improves quality of life. In June 2025, the U.S. Food and Drug Administration approved Mavrix Bio’s investigational new drug application for MVX-220. This allows the initiation of a first-in-human clinical trial evaluating the safety, tolerability, and efficacy of the gene therapy in children and adults with Angelman syndrome caused by diverse genetic anomalies.

Angelman Syndrome Epidemiology

Angelman syndrome affects approximately 1 in 15,000 individuals globally, with an estimated 500,000 cases worldwide. Developmental delays typically appear between 6 to 12 months of age, while seizures commonly begin between 2 to 3 years. The growing awareness and improved diagnostics have supported drug development efforts. Current pipeline drugs target the underlying genetic causes and aim to improve motor function, communication, and seizure control in affected individuals.

Angelman Syndrome – Pipeline Therapeutic Assessment

Angelman Syndrome Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III, with nearly 43%, covers a major share of the total Angelman syndrome clinical trials. This reflects strong clinical advancement and late-stage development. Phase I and Phase II each account for 28%, indicating a balanced focus on early and mid-stage innovation. These active developments are likely to drive significant progress and treatment options in the Angelman syndrome pipeline.

Angelman Syndrome Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the Angelman syndrome pipeline analysis include small molecules, antisense oligonucleotides, and neuroactive compounds. The Angelman syndrome report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Angelman syndrome.

Gene therapies are gaining traction in the Angelman syndrome treatment pipeline as targeted approaches to address the genetic root causes. For instance, MVX-220, developed by MavriX Bio, is an adeno-associated virus (AAV)-based gene therapy designed to restore UBE3A gene expression. It recently received Investigational New Drug clearance to initiate a first-in-human Phase 1/2 clinical trial, ASCEND-AS.

Angelman Syndrome Clinical Trials – Key Players

The EMR report for the Angelman syndrome pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed Angelman syndrome therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in Angelman syndrome clinical trials:

• Ionis Pharmaceuticals, Inc.
• Ultragenyx Pharmaceutical Inc.
• Hoffmann-La Roche
• Neuren Pharmaceuticals Limited
• Ovid Therapeutics Inc.
• Biogen
• Astellas Pharma

Angelman Syndrome – Emerging Drugs Profile

Key Questions Answered in the Angelman Syndrome Pipeline Insight Report

• Which companies/institutions are leading the Angelman syndrome drug development?
• What is the efficacy and safety profile of Angelman syndrome pipeline drugs?
• Which company is leading the Angelman syndrome pipeline development activities?
• What is the current Angelman syndrome commercial assessment?
• What are the opportunities and challenges present in the Angelman syndrome pipeline landscape?
• Which company is conducting major trials for Angelman syndrome drugs?
• Which companies/institutions are involved in Angelman syndrome collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in Angelman syndrome?

Reasons To Buy This Report

The Angelman Syndrome Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for Angelman syndrome. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into Angelman syndrome collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Global Clinical Trials Market

Neurological Disease Treatment Market Report and Forecast

Neurology Clinical Trials Market Report and Forecast

Chile Neurology Devices Market Report and Forecast